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A B S T R A C T
Retinal ganglion cell (RGC) degeneration is the root cause for vision loss in glaucoma as well as in other forms of
optic neuropathy. A variety of studies have implicated abnormal mitochondrial quality control (MQC) as con-
tributing to RGC damage and degeneration in optic neuropathies. The ability to differentiate human pluripotent
stem cells (hPSCs) into RGCs provides an opportunity to study RGC MQC in great detail. Degradation of damaged
mitochondria is a critical step of MQC, and here we have used hPSC-derived RGCs (hRGCs) to analyze how
altered mitochondrial degradation pathways in hRGCs affect their survival. Using pharmacological methods, we
have investigated the role of the proteasomal and endo-lysosomal pathways in degrading damaged mitochondria
in hRGCs and their precursor stem cells. We found that upon mitochondrial damage induced by the proton
uncoupler carbonyl cyanide m-chlorophenyl hydrazone (CCCP), hRGCs more efficiently degraded mitochondria
than did their precursor stem cells. We further identified that for degrading damaged mitochondria, stem cells
predominantly use the ubiquitine-proteasome system (UPS) while hRGCs use the endo-lysosomal pathway. UPS
inhibition causes apoptosis and cell death in stem cells, while hRGC viability is dependent on the endo-lysosomal
pathway but not on the UPS pathway. These findings suggest that manipulation of the endo-lysosomal pathway
could be therapeutically relevant for RGC protection in treating optic neuropathies associated with mitophagy
defects. Endo-lysosome dependent cell survival is also conserved in other human neurons as we found that
differentiated human cerebral cortical neurons also degenerated upon endo-lysosomal inhibition but not with
proteasome inhibition.
1. Introduction
Optic neuropathies such as glaucoma, Leber's hereditary optic
neuropathy (LHON), dominant optic atrophy (DOA) [1] and several
other neurodegenerative diseases have been reported to be associated
with abnormal mitochondrial quality control (MQC) [2,3]. Almost all
LHON patients carry a mutation in one of the complex I subunits of the
mitochondrial respiratory chain at 3460G > A (ND1), 11778G > A
(ND4) or 14484T > C (ND6). Identification of such mutations is in fact
used for definitive LHON diagnosis [4]. Nearly 75% of DOA patients are
diagnosed with mutations in the OPA1 gene, which is a nuclear en-
coded inner mitochondrial membrane protein involve in mitochondrial
fusion [5]. Genetic analysis has identified several gene mutations as-
sociated with the primary open-angle glaucoma (POAG) patients [6,7].
Additionally, a small subset POAG patients have been found to have
mutations in the Optineurin (OPTN) gene [8], which is a key player in
mitochondrial autophagy (mitophagy) [9]. In almost all of these optic
neuropathies, irreversible damage of retinal ganglion cells (RGCs) leads
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to vision loss and can result in complete blindness [1].
MQC involves mitochondrial dynamics (fission/fusion), biogenesis
and degradation. While each step of MQC is important for mitochon-
drial homeostasis, defects in mitochondrial degradation are particularly
severe, as they result in an accumulation of damaged mitochondria and
can ultimately lead to cell death through apoptosis [10–12]. Macro-
autophagy is a conserved catabolic process in which damaged proteins
or organelles are degraded by forming a double membrane structure
around them, allowing complex protein interactions known as autop-
hagosomes. These autophagosomes then fuse with the lysosomes where
the damaged materials are degraded [13–15]. Selective degradation of
damaged mitochondria through the lysosome-mediated autophagic
pathway is called mitophagy [16,17]. Apart from cell autonomous
mitophagy, a recent report has also shown that RGCs in mice shed
mitochondria at the optic nerve head (ONH), a process mediated by
adjacent astrocytes referred to as transmitophagy [18].
Advanced imaging techniques have been very powerful to under-
stand the details of retinal ganglion cell layer in living eye [19], how-
ever these techniques still lack the ability to identify mitochondrial
abnormality in RGC layer. In vivo models as well as cultured cells have
been instrumental in understanding molecular details of MQC pathways
and the pathophysiology associated with abnormal MQC [20]. How-
ever, mitochondrial abnormalities have different consequences in dif-
ferent cells, and one powerful example of this is the propensity for
certain mitochondrial mutations to specifically affect RGCs in mi-
tochondrial optic neuropathies [4,5,8]. Also, recent single-cell tran-
scriptomic studies further suggest that there are many basic differences
between rodent and primate retinal cells [21]. Hence, an increased
understanding of MQC in human RGCs could be therapeutically im-
portant for the mitochondrial optic neuropathies. Therefore, in order to
promote the understanding and treatment of human optic neuropathies
we feel it is important to study MQC in the context of human RGCs, and
to do so we have been studying stem-cell derived human RGCs using in
vitro models of mitochondrial stress. Furthermore, a stem cell-based
approach will enable us to study the adaption of the MQC pathways
during the course of RGC differentiation by comparing the process in
stem cells versus in differentiated hRGCs.
Healthy mitochondrial homoeostasis in adult human stem cells is
required to prevent stem cell aging and to maintain pluripotency [22].
The endo-lysosomal and proteasomal pathways are the two major cel-
lular quality control pathways for clearing damaged organelles and
proteins. However, it is unclear how hRGCs and their origin stem cells
use either pathway for maintaining mitochondrial homeostasis. Studies
in mice have shown that mitophagy is required for the self-renewal
[23,24] and differentiation [25] of hematopoietic stem cells (HSCs) as
well as for cancer stem cell maintenance [26,27] in humans. The ubi-
quitin proteasome system (UPS) is highly active in hPSCs and upon
cellular differentiation, the proteasome remains active but at a reduced
level [28,29]. It is still unclear if hPSCs use the UPS system for de-
grading damaged mitochondria.
Several studies in mice have shown that programmed mitophagy is
required for RGC differentiation [30,31], and the E50K mutation in the
autophagy adaptor protein optineurin (OPTN) has been shown to cause
mitochondrial defects and RGC death [32]. Additionally, the OPTNE50K
mutation is associated with some cases of so-called normal-tension
glaucoma (NTG) [8]. It is well accepted that mitochondrial dynamics
and quality control are central to mouse RGC viability [33]; however,
the role of the lysosomal-autophagy and proteasomal pathways in de-
grading damaged mitochondria in hRGCs and its effect on hRGC sur-
vival are not yet understood.
In this study, we used small molecule-based hPSC differentiation
and bead-based immunopurification to obtain highly pure, well-char-
acterized hRGCs [34]. These hRGCs were used to investigate the role of
the endo-lysosomal and the proteasomal pathways in clearing damaged
mitochondria in comparison to their precursor stem cells. Our study
indicates that hRGCs predominantly use the endo-lysosomal pathway
for degrading damaged mitochondria to prevent apoptosis, whereas
hPSCs primarily use the proteasomal pathway for mitochondrial
clearance and cell survival.
2. Materials and methods
2.1. Reporter line generation
H9 and H7 (WiCell, Madison, https://www.wicell.org) human em-
bryonic stem cells with the BRN3B–P2A-tdTomato-P2A-THY1.2 re-
porters were developed in our lab [34] and the H7 reporter line con-
tains additional TRE:Cas9 cassette as described in Ref. [35] but without
Cas9 induction for this study. Both the reporter lines are referred here
as H9-ESCs and H7-ESCs and the differentiated RGCs are H9-RGCs and
H7-RGCs respectively. iPSCs (EP1) were developed in our lab [36] and
used here as EP1-iPSCs. EP1 with the BRN3B–P2A-tdTomato-P2A-
THY1.2 reporter was made by CRISPR/Cas9-based gene editing using a
gRNA plasmid with Cas9 and puromycin selection, and the donor
plasmid with the reporter genes as used before [34]. In Brief, EP1-iPSCs
were transfected with the DNA-In stem reagent (MTI-GlobalStem/
ThermoFisher) followed by fresh media change after 24 h. After 40 h of
transfection, cells were selected against puromycin (0.9 μg/ml) for 24 h
and recovered for 4–5 days with fresh media without puromycin. To
isolate positive clones, cells were re-plated at clonal density, and single
colonies were genotyped by PCR as described in the previous study
[34].
2.2. Human RGC differentiation and immunopurification
RGC reporter lines were plated on 1% (vol/vol) Matrigel-GFR (BD
Biosciences) coated dishes and differentiated using small molecules as
described in the previous study [34]. In brief, stem cells were plated on
Matrigel coated plate at ~53K/cm2 density in mTeSR media (Stemcell
Technologies) with 5 μM blebbistatin and incubated in the hypoxia
incubator (37 °C, 10% CO2, 5% O2), this day referred as day minus one
(d-1). After 24 h, on d0 cells were transferred into the normoxia in-
cubator (37 °C, 5% CO2, 20% O2) for differentiation and mTeSR was
replaced with the differentiation media (N2B27: 1:1 mixture of DMEM/
F12 and Neurobasal, 1X GlutaMAX supplement, 1X antibiotic-anti-
mycotic, 1% N2 supplement and 2% B27 supplement (all from Ther-
moFisher Scientific). On d1, the following small molecules were added
with full exchange of N2B27 media: Forskolin (FSK; 25 μM, Cell Sig-
naling Technology), Dorsomorphin (DSM; 1 μM, Stemcell Technolo-
gies), IDE2 (2.5 μM, R&D Systems) and Nicotinamide (NIC; 10 mM,
Sigma-Aldrich). All small molecules were treated with full exchange of
N2B27 media every other day until d6, between d6 to d10 cells were
treated with FSK and NIC, d10-18 with FSK, d18-30 with FSK and DAPT
(10 μM, Sigma-Aldrich), and from d30 onwards only with N2B27
media. Successful RGC differentiation was monitored by tdTomato ex-
pression. RGC purification was done during day 40–45 after dissocia-
tion with Accumax cell dissociation solution (Sigma-Aldrich) followed
by purification using CD90.2 (THY1.2) MicroBeads and magnetic acti-
vated cell sorting system (MACS, Miltenyi Biotec) as described in the
previous studies [34,37].
2.3. hPSC and RGC maintenance and drug treatments
hPSCs and RGCs were cultured and maintained on 1% (vol/vol)
Matrigel-GFR (BD Biosciences) coated dishes in mTeSR and N2B27
media [34] respectively. Stem cells and RGCs were cultured in 37 °C
hypoxia (10% CO2, 5% O2) and normoxia (5% CO2, 20% O2) in-
cubators, respectively. The following drugs were used in this study:
CCCP (Sigma), bafilomycin A1 (Baf, Sigma), hydroxychloroquine (HCQ,
Fisher Scientific), bortezomib (Selleckchem), oligomycin (Millipore),
antimycin (Sigma), oligomycin-antimycin (OA) drug combination used
at 10 μM and 4 μM concentrations respectively, and MG132 (Sigma).
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All the drugs were dissolved in DMSO except hydroxychloroquine
which is soluble in water and the stock solutions were prepared in a
way such that each condition requires similar volume of drug solution.
For hydroxychloroquine treatment similar volume of DMSO was added
to the culture followed by drug addition. All the treatments were
compared to the corresponding DMSO group.
2.4. Mitochondrial DNA quantification by qPCR
After purification, RGCs were plated on Matrigel-coated tissue cul-
ture plates and grown for three days prior to the indicated drug treat-
ments. Cells were dissociated using Accumax for 15min and quenched
with the N2B27 media followed by centrifugation at 300×g for 5min.
DNA was isolated from the cell pellets using DNeasy Blood and Tissue
kit (Qiagen) followed by simultaneous quantification of the mitochon-
drial and nuclear DNA content within the same sample using TaqMan
chemistry (Thermo Fisher) with StepOnePlus Real-Time PCR system
(Applied Biosystems). Human mitochondrial DNA was detected via
measurement of the very stable region on the mitochondrial ND1 gene
[38] using following primers [39];
Forward: 5′ CCTTCGCTGACGCCATAAA3′, reverse: 5′TGGTAGATG
TGGCGGGTTTT3′, ND1-probe: 6FAM-5′TCTTCACCAAAGAGCC3′-
MGBNFQ (6FAM and the MGBNFQ are the fluorescence reporter and
quencher respectively). For an internal control, nuclear DNA content
was measured using the human RNase P gene (TaqMan Copy Number
Reference assay Catalog # 4403326).
For hPSCs (H9, H7-ESCs and EP1-iPSCs), 15,000 cells were plated
on each well of a Matrigel-coated 96-well dish. After 24 h of recovery,
cells were treated with the indicated drugs and dissociated with
Accutase (Millipore-Sigma) and quenched with mTeSR media con-
taining blebbistatin (Sigma), followed by centrifugation at 300×g for
5min to pellet the cells. Mitochondrial content for each sample was
measured as explained above.
2.5. Mitochondrial quantification by flow cytometry
Flow cytometry-based measurements were done using a mitochon-
dria specific dye, mito tracker deep red (MTDR, Molecular probes)
using the cell sorter SH800 (Sony) on analyzer mode.
10,000–20,000 cells were analyzed at the FL-4 channel (far-red) to
measure MTDR intensity. For 3 h CCCP treatments (Fig. 1G–I), cells
were labelled before treatment, while for 24 h treatments, cells were
labelled afterwards with media containing 10 nM MTDR for 15 min at
37 °C. Cells were dissociated and centrifuged as explained in the qPCR
method followed by suspension in media without MTDR for flow ana-
lysis.
2.6. Cell viability and apoptosis measurements
Cell viability and apoptosis were measured using ApoTox-Glo
Triplex assay kit (Promega) following manufacturer's guideline with the
CLARIOstar microplate reader (BMG LABTECH). Cell viability was
measured by the ratio of fluorescence intensity between 400 nm (via-
bility) and 482 nm (cytotoxicity) channels, and apoptosis was measured
by luminescence-based caspase-3/7 activity. hPSCs (10,000/well) and
RGCs (15,000/well) were plated in each well of Matrigel-coated 96-
well dishes in mTeSR containing blebbistatin and N2B27 media re-
spectively. After one day (hPSCs) and three days (RGCs) of recovery,
cells were treated with the indicated drugs for 24 h and analyzed for
cell viability and apoptosis.
2.7. Image acquisition to show cell viability
Images were acquired after indicated treatments using an EVOS FL
Imaging System (ThermoFisher Scientific).
2.8. Lysosome/acidic vesicles inhibition assay
20,000 H9-RGCs were plated and grown on Matrigel-coated glass-
bottom dishes (MatTek) in N2B27 media for three days in the 37 °C
normoxia incubator. After 24 h of treatment with the endo-lysosomal
inhibitors Baf or HCQ, media was replaced with 100 μl of media con-
taining pH sensitive pHrodo-green conjugated dextran solution
(ThermoFisher Scientific) (100 μg/ml) for 20min followed by a fresh
media exchange after a brief wash. Confocal (Zeiss LSM 710) live
images were acquired using the live cell set up with plan-apochromat
40x/oil objective with 1.4 numerical aperture. pHrodo-Green and
tdTomato-expressing RGCs were detected with the 488 nm and 560 nm
laser lines respectively.
2.9. Human cortical neuron differentiation
Cortical neurons were differentiated from H1-ESCs as described in
Xu et al. [40]. Experiments were performed on 100–120 days of post-
differentiated cortical neurons.
2.10. Immunofluorescence and imaging
20,000 purified RGCs were plated on matrigel-coated glass-bottom
dishes (MatTek) for three days followed by 24 h treatment with the
indicated drugs. Cells were fixed with 4% paraformaldehyde in PBS for
15 min at 37 °C followed by 1 h of blocking at room temperature with
blocking solution (PBS with 5% donkey serum and 0.2%Triton X-100).
The following primary antibodies were used overnight at 4 °C in
blocking solution: Rabbit-anti-ubiquitin (Cell Signaling Technology,
1:200 dilution), Rabbit-anti-RBPMS (GeneTex, 1:200 dilution) and
Mouse-anti-TUBB3 (BioLegend, 1:200 dilution). Samples were washed
for three times for 5min each with washing solution (PBS with 1%
donkey serum and 0.05%Triton X-100) and incubated with the sec-
ondary antibodies (1:500 dilution) in blocking solution for 1 h at room
temperature. Following the secondary antibody, samples were again
washed three times, with DAPI added in the second wash.
Cultured human cortical neurons of 100–120 days post-differentia-
tion were immunostained as above with primary antibodies against
MAP2 (Mouse-anti-MAP2, Sigma, 1:200 dilution), VGLUT1 (Mouse-
anti-VGLUT, SYSY, 1:2500 dilution) and VGAT (Rabbit-anti-VGAT,
SYSY, 1:500 dilution). Confocal images were acquired using LSM 710
(Zeiss) as done for pHrodo-Green, but without the live set-up.
2.11. Statistical analysis
Statistical comparisons between two data sets were done with the
Student's t-test. One-way ANOVA tests were performed for analysis
containing three or more independent groups followed by post hoc t-
test for individual groups with respect to the control DMSO group
(Table-1).
3. Results
3.1. RGCs are more efficient in degrading damaged mitochondria than their
precursor stem cells
To investigate mitochondrial degradation in both differentiated
human RGCs and in the stem cells from which they originated, we used
a CRISPR/Cas9 mediated genetically engineered human embryonic
stem cell (hESC-H9) reporter line with a P2A-tdTomato-P2A-Thy1.2
construct introduced into the endogenous RGC-specific POU4F2
(BRN3B) locus [34]. Small molecule-based differentiation followed by
immunopurification of Thy1.2-expressing cells yields highly enriched
RGCs, which are positive for RGC specific markers such as RBPMS [41]
and the neuronal marker TUBB3 (Supplemental Fig. S1) and that have
been well-characterized transcriptomically and electrophysiologically
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[34,42]. The reporter line will be referred as “H9-ESCs” and the cor-
responding RGCs as “H9-RGCs.” To study the effect of mitochondrial
damage on RGCs and stem cells, we have used the mitochondrial un-
coupler CCCP. Upon mitochondrial damage with CCCP for 3 h, H9-ESCs
showed no reduction in their mitochondrial level (Fig. 1A), as measured
by a qPCR assay that compares the level of mitochondrial gene ND1
DNA to that of nuclear gene RNase P DNA. This result was surprising
because CCCP has been reported to induce mitophagy within 1 h of
exposure [43], and hence we expected to see a decrease in mitochon-
drial content. We hypothesized that due to this apparent lack of mi-
tochondrial clearance in the H9-ESC cells, which would presumably
lead to a buildup of CCCP-induced damaged mitochondria, there would
be an increase of cell death. However, even with 24 h treatment with
CCCP there was no detectable cell death in H9-ESCs (Fig. 1B and C).
Contrary to the situation with H9-ESCs, CCCP treatment for 3 h reduced
the mitochondrial content of H9-RGCs (Fig. 1D). As with the H9-ESCs,
CCCP treatment did not result in RGC cell death at 24 h (Fig. 1E and F).
These results suggest that RGCs may be more efficient in degrading
damaged mitochondria than their precursor stem cells.
With the unexpected result of no change in mitochondrial content
with CCCP and yet no cell death for H9-ESCs, we next asked whether
ESCs might be clearing up damaged mitochondria while simultaneously
synthesizing more mitochondria to keep up with their metabolic needs
for rapid cell division, and this simultaneous new synthesis might be
masking possible mitochondrial degradation. To test this possibility, we
tracked mitochondrial levels upon CCCP treatment using the mi-
tochondria-specific dye mitotracker deep red (MTDR) followed by flow
cytometry [44] (Supplemental Fig. S2). MTDR covalently binds to the
reduced thiols within the mitochondria matrix proteins and once
bound, MTDR remains in the mitochondria independent of mitochon-
drial membrane potential [45,46]. CCCP lowers mitochondrial mem-
brane potential which could affect initial MTDR binding; to avoid this
potential artifact mitochondria were labelled with the MTDR dye prior
to CCCP treatment. After which appropriate incubation was followed
with flow cytometry-based analysis of mitochondrial content (Fig. 1G).
With this experimental paradigm, mitochondria synthesized after CCCP
treatment will not be labelled, and thus will not be detected, and hence
they will not mask possible degradation of pre-existing damaged mi-
tochondria. Interestingly, we observed reduced mitochondria levels
with increasing doses of CCCP for H9-ESCs (Fig. 1H) and saw similar
but more dramatic reduction in mitochondria in H9-RGCs at 5 and
10 μM CCCP (Fig. 1H). To make sure this was not a cell line-specific
effect, we performed a parallel experiment with an iPSC-derived
POU4F2 reporter line (EP1-iPSCs), again examining both un-
differentiated stem cells and differentiated RGCs (EP1-RGCs). In
agreement with the H9 results, the iPSCs showed mitochondrial de-
gradation with increasing doses of CCCP and the corresponding RGCs
degraded mitochondria more efficiently compared to the un-
differentiated iPSCs (Fig. 1I). Of note, EP1-iPSCs showed relatively
Table 1
One-way ANOVA test for group of data containing three or more data sets and




Post hoc test with respect to control (p value)
Fig. 1A 1.3226E-05 CCCP (10.0 μM): 1.9045E-05
CCCP (20.0 μM): 1.32723E-05
Fig. 1B 0.36823588 CCCP (10.0 μM): 0.24992561
CCCP (20.0 μM): 0.15533524
Fig. 1D 0.00696819 CCCP (10.0 μM): 0.102379
CCCP (20.0 μM): 0.00018268
Fig. 1E 0.27528422 CCCP (10.0 μM): 0.20314162
CCCP (20.0 μM): 0.14190736
Fig. 1J 6.288E-07 CCCP (10.0 μM): 0.00068674; CCCP (20.0 μM):
1.07961E-06
Fig. 1K 1.6562E-05 CCCP (10.0 μM): 0.00027468
CCCP (20.0 μM): 0.00014416
Fig. 2A 0.00333067 Baf (50.0 nM): 0.02347454
HCQ (30.0 μM): 0.19815269
CCCP (10.0 μM): 0.89069482
CCCP (10.0 μM) + Baf (50.0 nM): 0.15636769
OA: 0.00972516
OA + Baf (50.0 nM): 0.03139634
Fig. 2B 1.6741E-08 Baf (50.0 nM): 0.00010464
HCQ (30.0 μM): 0.00105926
CCCP (10.0 μM): 0.24992561
CCCP (10.0 μM) + Baf (50.0 nM): 5.65264E-05;
OA: 2.70799E-07
OA + Baf (50.0 nM): 1.94566E-08
Fig. 2C 2.4542E-06 Baf (50.0 nM): 0.0060723
HCQ (30.0 μM): 0.06146984
CCCP (10.0 μM): 0.10332896
CCCP (10.0 μM) + Baf (50.0 nM): 0.0001987
OA: 0.00134962
OA + Baf (50.0 nM): 0.00029999
Fig. 2H 0.00193593 Baf (50.0 nM): 0.26729767
HCQ (30.0 μM): 0.01818717
CCCP (10.0 μM): 0.07470509
CCCP (10.0 μM) + Baf (50.0 nM): 0.49075726;
CCCP (10.0 μM) + HCQ (30.0 μM): 6.50831E-09
Fig. 2I 3.41207E-06 Baf (50.0 nM): 0.0005702
HCQ (30.0 μM): 0.00035478
CCCP (10.0 μM): 0.20314162
CCCP (10.0 μM) + Baf (50.0 nM): 0.00033786;
CCCP (10.0 μM) + HCQ (30.0 μM): 1.10269E-05
Fig. 2J 6.8186E-05 Baf (50.0 nM): 0.00259663; HCQ (30.0 μM):
1.30404E-05; CCCP (10.0 μM): 0.00146037; CCCP
(10.0 μM) + Baf (50.0 nM): 0.00278443; CCCP
(10.0 μM) + HCQ (30.0 μM): 0.00392949
Fig. 3A 0.00080816 Bort (50.0 nM): 0.21089911
Bort (500.0 nM): 0.00263605
Bort (1000.0 nM): 0.00060078
Fig. 3B 0.03867105 Bort (50.0 nM): 0.25931389
Bort (500.0 nM): 0.02038087
Bort (1000.0 nM): 0.00686592
Fig. 3C 0.29285313 Bort (50.0 nM): 0.25931389
CCCP (10.0 μM): 0.89069482
CCCP (10.0 μM) + Bort (50.0 nM): 0.00879123
Fig. 3I 5.9384E-08 Bort (15.0 nM): 1.7877E-06; Bort (50.0 nM):
0.00015752; Bort (500.0 nM): 7.07749E-05;
Bort (1000.0 nM): 4.18868E-05
Fig. 3L 9.6407E-05 Bort (15.0 nM): 1.00596E-05
Bort (50.0 nM): 0.00030353
Fig. 3 N 0.00954914 MG132 (10.0 μM): 3.14391E-05; MG132
(20.0 μM): 0.11225478
Fig. 3O 0.0737521 MG132 (10.0 μM): 0.06210585
MG132 (20.0 μM): 0.04643869
Fig. 4B 0.2133412 HCQ (30.0 μM): 0.43894442
HCQ (60.0 μM): 0.02783898
Fig. 4C 0.06621655 HCQ (30.0 μM): 0.03771928
HCQ (60.0 μM): 0.00060646
Fig. 4D 0.36246771 Bort (50.0 nM): 0.39282229
Bort (500.0 nM): 0.32810538
Fig. 4E 5.8274E-05 Bort (50.0 nM): 0.00011123






Post hoc test with respect to control (p value)
Bort (15.0 nM): 5.369E-05; Bort (50.0 nM):
0.00012986
Bort (500.0 nM): 0.00030233
Bort (1000.0 nM): 0.0032803
Fig. S5B 6.9674E-05 Bort (15.0 nM): 0.00018375
Bort (50.0 nM): 0.00498865; Bort (500.0 nM):
4.76206E-06;
Bort (1000.0 nM): 0.00020643
Fig. S5C 3.4096E-05 Bort (15.0 nM): 0.00022683
Bort (50.0 nM): 0.00016114
Bort (500.0 nM): 0.00018035
Bort (1000.0 nM): 0.00413441
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reduced mitochondrial clearance compared to the H9-ESCs (Fig. 1H and
I) and upon CCCP damage, correspondingly showed reduced cell via-
bility and increased apoptosis (Fig. 1J and K), further supporting the
hypothesis that inefficient degradation of damaged mitochondria may
lead to apoptotic cell death. It should be noted that in this experiment,
based upon prior protocols, the stem cells were cultured and treated
Fig. 1. Mitochondrial degradation in stem cells and hRGCs upon CCCP treatment. (A, D) Mitochondrial content analyzed by qPCR for the mitochondrial gene
ND1 and normalized with-respect-to (w.r.t) the nuclear gene RNase P. Shown are ΔΔct fold change relative to the DMSO control after 3 h treatment with the indicated
CCCP doses for both h9-ESCs (A) and H9-RGCs (D). Data shown are from three independent biological replicates with three technical replicates for each biological
replicate. (B, E) Cell viability measurements of H9-ESCs (B) and H9-RGCs (E) after 24 h treatment with the indicated doses of CCCP. Cell viability was measured
using the fluorescence based ApoTox-Glo triplex assay kit and normalized w.r.t DMSO control. Data shown are from three independent biological replicates. (C, F)
Brightfield images shown are H9-ESCs after 24 h treatment with CCCP (C), fluorescence images shown are in the red channel for tdTomato expressing H9-RGCs after
24 h CCCP treatments (F). (G–I) Mitochondrial level analyzed by flow cytometry using the mitochondria specific dye MTDR followed by CCCP treatments for 3 h.
Chart (G) shows the experimental design while the graphs show loss of mitochondria labelled MTDR intensity normalized w.r.t DMSO control at different CCCP doses
for H9-ESCs (H) and EP1-iPSCs (I) compared to the corresponding RGCs. Data presented are from 3 to 10 independent biological replicates and statistical analysis is
done between stem cells and corresponding RGCs at the indicated treatments. (J, K) Cell viability (J) and apoptosis by luminescence-based caspase-3/7 activity (K)
were measured for EP1-iPSCs using ApoTox-Glo triplex assay kit and normalized w.r.t DMSO control after 24 h treatment with the indicated drugs using three
independent biological replicates. Scale bars, 1000 μm (C) and 200 μm (F). Error bars are SEM. **, p-value < 0.005. (For interpretation of the references to colour in
this figure legend, the reader is referred to the Web version of this article.)
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with CCCP in the hypoxic (10% CO2, 5% O2) condition while the RGCs
were cultured under normoxic condition (5% CO2, 20% O2). Given this
difference, we asked whether the observed difference in mitochondrial
degradation between stem cells and corresponding RGCs might be due
to the difference in culture conditions. To test this, both H9-ESCs and
the corresponding RGCs were cultured and treated with CCCP under
similar normoxic conditions followed by mitochondrial measurements.
In agreement with our prior findings (Fig. 1H and I), we observed in-
creased mitochondrial degradation in the H9-RGCs compared to their
precursor stem cells (Supplemental Fig. S3), suggesting that hRGCs are
more efficient in degrading damaged mitochondria irrespective of their
culture conditions. Investigating the pathways involved in degrading
damaged mitochondria in hRGCs could be therapeutically important as
modulation of the pathways involved could potentially be used to en-
hance hRGC survival under specific conditions.
3.2. The endo-lysosomal pathway is required for hRGCs but not for hESCs
to degrade damaged mitochondria
To better define possible cell type-specific mechanisms of mi-
tochondrial quality control in hRGCs, we first tested the role of the
endo-lysosomal pathway in degrading damaged mitochondria in hPSCs
and hRGCs. Mitochondrial levels were measured after CCCP treatment
both in the presence and absence of the endo-lysosomal inhibitors hy-
droxychloroquine (HCQ) [47] and Bafilomycin A1 (Baf) [48]. qPCR-
based analysis showed that individual treatment with CCCP, HCQ, or
Baf, as well as CCCP with Baf, did not affect mitochondrial level in H9-
ESCs (Fig. 2A). Tracking MTDR labelled mitochondrial content upon
CCCP treatment showed mitochondrial degradation in hPSCs (Fig. 1H
and I). Our inability to detect an increase in mitochondria levels upon
endo-lysosomal inhibition suggests the existence of an alternative
pathway in H9-ESCs for degrading damaged mitochondria. We ob-
served significant cell death and apoptosis when cells were treated with
Baf but did not observe similar cell death with HCQ treatment (Fig. 2B
and C). This could be due to the requirement of endo-lysosomal activity
and the autophagy pathway for other cellular functions, such as non-
mitochondrial protein and organelle homeostasis [49,50]. The differ-
ential effects of Baf and HCQ on H9-ESC survival could be due to the
distinct modes of action of the two inhibitors [51].
We next tested if inhibition of the mitochondrial electron transport
chain (mETC) with oligomycin-antimycin (OA) would cause mi-
tochondrial degradation in ESCs. Interestingly, we did not observe re-
duced mitochondrial levels with OA treatment; on the contrary, we
observed increased mitochondrial levels when cells were treated alone
or in combination with Baf (Fig. 2A). This finding is consistent with a
prior report that inhibition of the mETC is associated with the inhibi-
tion of autophagy [52], which could account for the observed increase
in mitochondrial content, and the increased cell death and apoptosis
with OA treatment (Fig. 2B and C). Since oligomycin has been reported
to increase inner mitochondria membrane potential (ΔΨm) [53,54], we
further asked if increasing ΔΨm by inhibition of the mitochondrial
permeability transition pore (mPTP) with cyclosporin A (CsA) [54]
could also block mitochondrial degradation. In agreement with the OA
result, we observed increased mitochondrial levels in H9-ESCs treated
with CsA (Fig. 2D and E). Presumably because inhibition of damaged
mitochondrial degradation can be toxic, CsA treatment also caused
increased cell death and activation of apoptosis (Fig. 2F and G).
To test whether H9-RGCs degrade damaged mitochondria via endo-
lysosomes, we blocked endo-lysosomal activity with Baf and HCQ. HCQ
(with and without CCCP), but not Baf, increased mitochondrial content
(Fig. 2H), indicating that HCQ is a more potent inhibitor of mitophagy
in H9-RGCs than in hESCs. As expected, presumably due to its inhibi-
tion of mitochondrial clearance, HCQ caused hRGC death and apoptosis
(Fig. 2I and J). Although we did not observe increased levels of mi-
tochondria with Baf treatment (Fig. 2H), we did observe increased H9-
RGC apoptosis and cell death (Fig. 2I and J). As an indication that they
were having their expected pharmacological activities, both Baf and
HCQ increased the pH of the acidic endo-lysosomal vesicles as shown
by a decrease in fluorescence dots of the pH-sensitive dye pHrodo-green
dextran (Supplemental Fig. S4). The explanation of the differences be-
tween the effects of Baf and HCQ is unclear, but may reflect that the two
drugs affect the endo-lysosomal compartments differently, which has
been reported [51].
The above data suggest differentiated RGCs are different from their
origin stem cells in terms of using endo-lysosomes for degrading da-
maged mitochondria. For stem cells, inhibition of endo-lysosomes was
toxic but did not increase mitochondrial content. But in H9-RGCs in-
hibition of the endo-lysosomal pathway both inhibited mitochondrial
degradation as well as reduced RGC survival, suggesting RGCs pre-
dominantly use the endo-lysosomal pathway for mitophagy and cellular
homeostasis. The choice for using the endo-lysosomal pathway versus
UPS to maintain healthy cellular homeostasis is critical for cell survival.
With the apparent difference between hESCs and hRGCs in using the
endo-lysosomal pathway and with the potential involvement of UPS in
neurodegenerative diseases [55], led us to ask about the role of UPS for
mitochondrial clearance and neuro-protection in hRGCs and their
origin stem cells.
3.3. The UPS is required for mitochondrial degradation and cell survival for
hPSCs but not for hRGCs
As an alternative to the endo-lysosomal pathway, the ubiquitin-
proteasomal system (UPS) is the other major cellular quality control
pathway for protein and organelle homeostasis [56]. We next in-
vestigated the role of UPS in mitochondrial clearance by using the drug
bortezomib to inhibit the proteasome's 20S core particle [57]. Un-
expectedly, we found that inhibiting proteasomes in H9-ESCs increased
mitochondrial levels in a dose dependent manner (Fig. 3A and B). We
next asked if proteasomal activity is required for the clearance of
acutely damaged mitochondria in H9-ESCs. To test this, we induced
mitochondrial damage by CCCP both in the presence and the absence of
bortezomib. In agreement with our hypothesis, we observed an increase
level of mitochondria when proteasomal clearance was blocked by
bortezomib compared to CCCP alone (Fig. 3C), suggesting that hPSCs
use the proteasomal pathway to degrade damaged mitochondria.
As accumulation of damaged mitochondria could lead to cellular
toxicity, we investigated whether inhibiting proteasomal activity could
lead to cell death for stem cells, and then examined the effect of this
same inhibition on the corresponding hRGCs. We observed severe cell
death for H9-ESCs with bortezomib treatment (Fig. 3D and E); however,
this effect was largely absent for the corresponding H9-RGCs (Fig. 3E,
H). To test if the observed effect was cell type specific, we also inhibited
proteasome function in two additional lines; EP1-iPSCs and H7-ESCs, as
well as their corresponding RGCs. Much to our surprise we saw a si-
milar high level of cell death for both the stem cell lines but not for the
corresponding differentiated RGCs (Fig. 3F and G; there was a slight
increase in cell death for EP1-RGCs but significantly less than that seen
with the undifferentiated EP1-iPSCs). In agreement with the increase in
cell death, proteasome inhibition also induced cellular apoptosis for all
of these three stem cell lines (Supplemental Figs. S5A–C). These data
suggest that proteasomal activity is critical for basal level mitochon-
drial clearance and survival of hPSCs, while hRGC survival is not de-
pendent upon proteasome activity.
To investigate if proteasomal activity is required for mitochondrial
degradation in hRGCs, we treated H9-RGCs with different doses of
bortezomib for 24 h followed by mitochondrial level measurements.
Interestingly, unlike hPSCs, inhibiting the UPS with bortezomib did not
increase the mitochondrial level in H9-RGCs (Fig. 3I and J). With the
observed differences in proteasomal regulation between hPSCs and
hRGCs, we next asked if the UPS is still active in the hRGCs. Ubiqui-
tinated proteins and organelles are degraded through the proteasome
[58,59], hence inhibiting UPS activity should increase total
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ubiquitinated protein levels where the system is normally active. In
support of our hypothesis, we found a bortezomib dose-dependent in-
crease in the ubiquitinated protein level in H9-RGCs (Fig. 3K and L). We
further tested the bortezomib results using another very potent pro-
teasome inhibitor, MG132 [57,60]. In agreement with the bortezomib
data, MG132 negligibly effected cell death or apoptosis in H9-RGCs
(Fig. 3M − O).
These results suggest a switch in the mitochondrial degradation
pathways from the proteasome to the endo-lysosomal pathway during
human RGC differentiation, making the lysosomal-autophagy pathway
a potential therapeutic target for improving mitochondrial health and
therefore hRGC survival in glaucoma and in other forms of optic neu-
ropathy patients. While these findings could be important for improving
hRGC health, we were additionally interested to see if these phenomena
are specific to hRGCs, or if they are also true for other types of human
neurons. To address this question, we differentiated human cortical
neurons and tested the effect of endo-lysosomal and proteasomal in-
hibition on them.
3.4. Human cortical neurons are susceptible to endo-lysosomal inhibition
but not proteasome inhibition
To study the role of proteasomal and endo-lysosomal pathways for
cortical neuron survival, we differentiated cortical neurons from human
stem cells (H1-ESCs) following published methods [61]. Cultured
human cortical neurons were tested and shown to be positive for ex-
pression of the mature neuronal marker microtubule-associated protein
2 (MAP2), inhibitory marker vesicular GABA transporter (VGAT), and
excitatory marker vesicular glutamate transporter (VGLUT) (Fig. 4A).
To test the effect of endo-lysosomal inhibition, cells were treated with
HCQ. Similar to hRGCs, we observed significant cell death and corre-
sponding activation of apoptosis (Fig. 4B and C), suggesting the endo-
Fig. 2. hRGCs, but not hESCs, predominantly use the endo-lysosomal pathway for degrading mitochondria. (A, D, H) qPCR-based analysis of the mi-
tochondrial content for H9-ESCs (A, D) and H9-RGCs (H) after 24 h treatment with the indicated drugs, the quantification and analysis are done as in (Fig. 1). Data
shown are from 3 to 5 independent biological replicates with three technical replicates for each biological replicate. (B, F, I) Shown are cell viability measurements
after 24 h treatment with the indicated drugs for H9-ESCs (B, F) and H9-RGCs (I), and are done as in (Fig. 1). (C, G, J) Quantifications represent cellular apoptosis,
measured by luminescence-based caspase-3/7 activity for H9-ESCs (C, G) and H9-RGCs (J). Data shown are from three independent biological replicates. (E) Flow
cytometry-based analysis of the MTDR labelled mitochondria for H9-ESCs after 24 h treatment with the indicated drug, quantification shows normalized average
intensity in the MTDR channel w.r.t DMSO from nine independent biological replicates. Error bars are SEM. **, p-value < 0.007; *, p-value < 0.05.
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Fig. 3. hESCs but not hRGCs predominantly use the proteasomal pathway for degrading mitochondria. (A, I) Flow cytometry-based analysis of the MTDR
labelled mitochondria in H9-ESCs (A) and H9-RGCs (I) after 24 h treatment with the indicated doses of bortezomib from three independent biological replicates. (B,
C, J) qPCR analysis of the mitochondrial content in H9-ESCs (B, C) and H9-RGCs (J) after 24 h treatment with the indicated drugs, as done in (Fig. 1). Data shown are
from three independent biological replicates with three technical replicates for each biological replicate. (D) Brightfield images showing cell death in the H9-ESCs
after 24 h treatment with the indicated bortezomib (Bort) dose. (E–G) Shown are cell viability measurements after 24 h treatment with bortezomib to the indicated
stem cells and corresponding RGCs as done in (Fig. 1). Data presented are from 3 to 4 independent biological replicates and statistical analysis is done between stem
cells and corresponding RGCs at the indicated treatments. (H, M) Fluorescence images shown are in the red channel for the tdTomato expressing H9-RGCs after 24 h
bortezomib (Bort) (H) and MG132 (M) treatments with the indicated doses. (K, L) Images shown are the sum projections of the confocal z-stacks on immuno-
fluorescence against ubiquitin in H9-RGCs after 24 h treatment with the indicated bortezomib doses (K), and the quantification shows the integrated fluorescence
intensity from the sum-projections averaged over 14 to 32 individual cells for each condition (L). (N, O) Quantifications represent cell viability (N) and cellular
apoptosis (O), measured by using the fluorescence based ApoTox-Glo triplex assay kit and luminescence-based caspase-3/7 activity for H9-RGCs at the indicated
treatment. Data presented are from three independent biological replicates. Scale bars, 400 μm (D, M), 200 μm (H) and 10 μm (K). Error bars are SEM. **, p-value <
0.007; *, p-value < 0.05. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
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lysosomal pathway is important for cellular homeostasis in cortical
neurons.
Next, we tested the effect of proteasomal inhibition by treating
cortical neurons with the proteasome inhibitor bortezomib.
Interestingly, like hRGCs, proteasome inhibition did not cause cell
death for human cortical neurons (Fig. 4D and E).
Taking together, our data suggest that the endo-lysosomal pathway
may be the predominant pathway for degrading damaged mitochondria
and maintaining cellular homeostasis for not only human RGCs but also
for cortical neurons suggesting such phenomena could be true for other
differentiated human cell types.
4. Discussion
Our study identifies pathways important for maintaining healthy
mitochondrial homeostasis in human RGCs and suggests a step forward
for developing strategies to enhance RGC viability under disease con-
ditions. The results shown here suggest three key points: first, human
Fig. 4. Effect of UPS and endo-lysosomal pathway inhibition on human cortical neuron survival. (A) Shown are the confocal images of immunofluorescence
against neuronal marker MAP2, excitatory marker VGLUT and the inhibitory marker VGAT in differentiated H1-ESCs. (B–E) After 24 h treatment with the indicated
drugs, cell viability (B, D) and apoptosis (C, E) were measured using ApoTox-Glo triplex assay kit. Data presented are from 3 to 6 independent biological replicates.
Scale bars are 20 μm. Error bars are SEM. **, p-value < 0.005; *, p-value < 0.05.
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RGCs are more efficient in clearing up damaged mitochondria than
their precursor stem cells; second, the proteasomal pathway is essential
for stem cell survival but not for RGCs; and third, during RGC ma-
turation from stem cells, the pathway for mitochondrial clearance and
cellular homeostasis shifts from the proteasomal to the endo-lysosomal
pathway.
While we observed that mitochondrial degradation in stem cells is
dependent on UPS, a question still remains on how proteasomes de-
grade mitochondria? An elegant study by Chan et al. (2011) [62]
suggests that this could happen by Parkin mediated activation of the
UPS. Upon its translocation to mitochondria, Parkin activates the 26S
proteasome, leading to the degradation of the mitochondrial outer
membrane proteins. For hPSCs, a similar mechanism may lead to UPS
mediated mitochondrial degradation as well. However, our data sug-
gest UPS dependent mitochondrial degradation could depend on the
mitochondrial inner membrane potential (ΔΨm). We have seen that
when ESCs were treated with OA or CsA, which are known to increase
ΔΨm [53,54], mitochondrial degradation was inhibited (Fig. 2A, D, E).
However, when treated with the uncoupler CCCP, which abolishes ΔΨm
[53], mitochondrial degradation was induced (Fig. 1H and I). This
suggests ΔΨm could negatively regulate UPS mediated mitochondrial
degradation. Further efforts will be required to understand the me-
chanism of how ΔΨm can regulate UPS mediated mitochondrial de-
gradation. Even though we observed that inhibition of endo-lysosomes
did not block mitophagy in ESCs, endo-lysosome involvement cannot be
ruled out, as a previous report had shown inhibiting lysosomes in-
creased mitochondrial content in hematopoietic stem cells (HSCs) [63].
Our study indicates that the endo-lysosomal pathway is the primary
route for degrading damaged mitochondria in hRGCs. This is significant
as it makes the endo-lysosomal pathway a potential therapeutic target
to enhance mitochondrial homeostasis to increase hRGC survival.
Consistent with our findings, genetic analyses have identified several
mutations in MQC related genes in various human optic neuropathies.
These mutations include: a mutation in the mitophagy adaptor protein
Optineurin (OPTN) in primary open-angle glaucoma (POAG) patients
[8]; mutations in the MQC pathway proteins Mitofusin1/2 (Mfn1/2)
which have also been associated with normal-tension glaucoma (NTG)
patients [64]; and mitochondrial DNA mutations affecting mitochon-
drial function have been shown to be causative for the other forms of
optic neuropathy such as LHON and mutation in the mitochondrial
fusion protein OPA1 for Dominant Optic Atrophy patients [65]. A cel-
lular-level intervention to maintain healthy mitochondria and mitigate
optic nerve disease progression will be aided by further increases in our
understanding of the damaged mitochondrial clearance pathways in
human RGCs. In support to this notion it has been found that improving
mitochondrial health could serve as a retinal neuroprotection me-
chanism [66].
5. Conclusion
A switch from the ubiquitin proteasome system to the endo-lyso-
somal pathway for mitochondrial degradation and cell survival during
RGC differentiation is potentially highly significant as it could reflect a
general shift in the homeostasis of other proteins and organelles as well.
While this study was done in vitro utilizing human stem cell derived
RGC cultures, our findings may also reflect the behavior of RGCs and
other retinal cells in vivo. The results presented here could have fol-
lowing implications; first, UPS-mediated protein degradation is an ATP-
dependent process and requires energy [67], avoiding the UPS for
protein and organelle homeostasis could represent an energy saving
strategy for the highly energy-dependent RGCs [68]; second, the endo-
lysosomal pathway being the primary mitochondria degradation
pathway for RGCs implicates this pathway as a possible therapeutic
target for RGC neuroprotection in mitochondria-based optic neuro-
pathies. Additionally, modulating the endo-lysosome pathway under
specific conditions could be effective for other neurodegenerative
diseases, since in our study this pathway was found to be essential in
stem-cell derived human cortical neurons, in addition to RGCs, sug-
gesting the potential application of these findings to other neurons that
may also use the endo-lysosomal pathway for their survival.
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